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Abstract
Neuronal cholinergic circuits have been implicated in cognitive function and neurological disease, but the role of
cholinergic signaling in other cellular populations within the brain has not been as fully defined. Here, we show that
cholinergic signaling mechanisms are involved in mediating the function of the choroid plexus, the brain structure
responsible for generating CSF and releasing various factors into the brain. The choroid plexus was found to
express markers of endogenous cholinergic signaling, including multiple nicotinic acetylcholine receptor (nAChR)
subtypes in a region-specific manner, and application of nicotine was found to induce cellular activation, as
evidenced by calcium influx in primary tissue. During intravenous nicotine self-administration in male rats, nicotine
increased expression of transthyretin, a protein selectively produced and released by the choroid plexus, and
microRNA-204 (mir-204), a transcript found in high levels in the choroid plexus and CSF. Finally, human choroid
plexus tissue from both sexes was found to exhibit similar nAChR, transthyretin and mir-204 expression profiles,
supporting the translational relevance of the findings. Together, these studies demonstrate functionally active
cholinergic signaling mechanisms in the choroid plexus, the resulting effects on transthyretin and mir-204
expression, and reveal the direct mechanism by which nicotine modulates function of this tissue.
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Introduction
Cholinergic neuronal signaling has been shown to mod-
ulate various aspects of cognition, motivated behavior,
and learning and memory function (Picciotto et al., 2012).
At the cellular level, acetylcholine activates nicotinic ace-
tylcholine receptors (nAChRs) or muscarinic AChRs. Such
receptor activation has been shown to modulate a variety
of cellular signaling processes, including neuronal excit-
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Significance Statement
Tobacco/nicotine dependence is the largest preventable cause of disease and death worldwide. The current
investigations establish the presence of cholinergic signaling mechanisms in the choroid plexus and
demonstrate nicotine-mediated changes in transthyretin and microRNA-204 (mir-204) expression. These
changes were attributed to nicotine’s direct actions on nicotinic acetylcholine receptors (nAChRs) in the
choroid plexus tissue. Therefore, these studies elucidate a previously unrecognized cholinergic neuroregu-
latory system, which may have relevant implications for disease states characterized by cholinergic
dysfunction, such as Alzheimer’s disease, as well as nicotine dependence.
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ability, gene expression, presynaptic release of neu-
rotransmitters, and synaptic plasticity (Gray et al., 1996;
Grady et al., 2001; Parikh et al., 2007; Dani et al., 2011). In
addition to normal physiological function, cholinergic sig-
naling has been associated with several neuropsychiatric
and neurodegenerative disorders, such as dementia, Alz-
heimer’s disease, Parkinson’s disease, and schizophre-
nia, in which a deficit in cholinergic function is proposed
to underlie disease-specific symptomology (Whitehouse
et al., 1982; Coyle et al., 1983; Bordia et al., 2007; Bohnen
and Albin, 2011; Sarter et al., 2012). Pharmacological
approaches targeting the cholinergic system have also
been the focus of multiple drug development efforts in the
clinical setting (Jorenby et al., 2006; McHardy et al.,
2017), and nicotine, the main psychoactive substance in
tobacco and e-cigarettes, directly acts on nAChRs to
mediate various aspects of drug dependence (Picciotto
et al., 1998; Fowler et al., 2011; Fowler and Kenny, 2014).
The choroid plexus is a structure comprised of epithelial
cells, which is localized throughout the ventricular system
of the brain. Historically, the main role of the choroid
plexus was attributed to the production of CSF. However,
more recent findings have begun to elucidate other func-
tions. For instance, CSF released from the choroid plexus
has been shown to regulate neurogenesis throughout the
lifespan (Lehtinen and Walsh, 2011; Lehtinen et al., 2011)
and to play a role in Alzheimer’s disease pathology (Bate-
man et al., 2006; Krzyzanowska and Carro, 2012; Potter
et al., 2013). The CSF-derived factors involved in these
functions may include growth factors (e.g., Igf2, BDNF,
and VEGF), proteins (e.g., transthyretin and apolipopro-
tein J), and could also include extracellular vesicles con-
taining various RNA species (Lehtinen et al., 2011;
Krzyzanowska and Carro, 2012; Ochoa et al., 2015; Lee
et al., 2016; Riancho et al., 2017; Derkow et al., 2018),
although the full extent of factors released by the choroid
plexus with relevance to disease pathology remains to be
elucidated. The extensive basolateral infoldings of the
choroid plexus afford significant surface area for the re-
lease and uptake of signaling factors, whereas tight gap
junctions and transporters regulate passage of sub-
stances between the blood and CSF (Balusu et al., 2016).
The rate of production of CSF is projected to allow for
turnover of approximately four times per day in humans
(Johanson et al., 2005), and thus, the levels of circulating
factors can be continuously regulated to influence neural
function. Choroid plexus epithelium is found throughout
the ventricular locations, including the lateral, third and
fourth ventricles. At each of these sites during develop-
ment, the choroid plexus has been proposed to differ in
structure and function (Johanson et al., 2005; Lun et al.,
2015a). While nicotine has been shown to be localized in
choroid plexus tissue in vitro (Spector and Goldberg,
1982), it has remained unknown as to whether nAChRs
are expressed and/or functionally mediate signaling within
the choroid plexus cells.
In the current studies, we sought to identify whether
endogenous cholinergic signaling mechanisms are local-
ized in choroid plexus epithelium. Initial evidence indi-
cated that nicotine could act directly to mediate choroid
plexus function, and thus, we assessed whether cholin-
ergic cells and nAChR subunits are differentially ex-
pressed across ventricular locations. Thereafter, we
examined whether chronic nicotine self-administration
would lead to altered expression of mRNA and miRNA in
a region-specific manner. Specifically, we focused our
investigations on the choroid plexus-specific protein, tr-
ansthyretin, which has been found to be increased in the
CSF during nicotine exposure, and microRNA-204 (mir-
204), which is expressed in high density in the choroid
plexus (Li et al., 2000, 2016; Oberwinkler et al., 2005).
Primary choroid plexus cell culture was used to provide
further evidence of nicotine’s direct impact on cellular
activation with calcium imaging. Finally, nAChR subunits,
transthyretin and mir-204 expression were examined in
tissue from human subjects, thus providing translational
relevance for the potential impact of these findings in
humans.
Materials and Methods
Animals
Adult, male Wistar rats (RRID:RGD_13508588; n  78)
weighing 275–300 g were obtained from Charles River
Laboratories and housed two to three per cage. ChAT-
IRES-Cre (B6;129S6-Chattm2(cre)Lowl/J; Stock 006410;
RRID:IMSR_JAX:006410) and ROSA26Sor-tdTomato re-
porter (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J;
Stock 007914; RRID:IMSR_JAX:007914) mice were ob-
tained from The Jackson Laboratory and bred within our
colony as hemizygous mating pairs. Both founder lines
were backcrossed on a C57BL/6J background (RRID:
IMSR_JAX:000664) for at least 10 generations before the
current breeding cross. Pups were weaned at 21 d of age
and housed three to five per cage. Adult male hemizygous
ChAT-IRES-Cre::Rosa-TdTomato mice (n  5) were used
to characterize the presence of cholinergic cells within the
choroid plexus. Rats and mice were maintained in an
environmentally controlled vivarium on a 12/12 h light/
dark cycle, and food and water were provided ad libitum.
All experimental subjects were randomly assigned to
treatment conditions. However, during self-administra-
tion, rats were mildly food restricted to 85–90% of their
free-feeding body weight, while water was maintained ad
libitum. All procedures were conducted in strict accor-
dance with ethical regulations outlined in the National
Institutes of Health Guide for the Care and Use of Labo-
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ratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of
California, Irvine.
Mouse genotyping
At 21 d of age, mouse pups were weaned and their tails
were clipped for genetic analysis. Subjects were geno-
typed by PCR with the following primers: ChAT-IRES-Cre:
5’-GTT TGC AGA AGC GGT GGG-3’ (wild type forward),
5’-CCT TCT ATC GCC TTC TTG ACG-3’ (mutant forward),
5’-AGA TAG ATA ATG AGA GGC TC-3’ (common re-
verse); Rosa-TdTomato 5’-AAG GGA GCT GCA GTG
GAG TA-3’ (wild type forward), 5’-CCG AAA ATC TGT
GGG AAG TC-3’ (wild type reverse), 5’-CTG TTC CTG
TAC GGC ATG G-3’ (mutant forward), 5’-GGC ATT AAA
GCA GCG TAT CC-3’ (mutant reverse).
Drugs
Mecamylamine hydrochloride (Tocris Bioscence) was
diluted in 0.9% sterile saline and injected subcutaneously
at a dose of 2 mg/kg. (-)-Nicotine hydrogen tartrate salt
(MP Biomedicals) was dissolved in 0.9% sterile saline (pH
7.4), and doses of nicotine refer to the free-base form.
Ketamine (KetaVed, Patterson Veterinary) and xylazine
(AnaSed, Patterson Veterinary) were diluted in sterile sa-
line and simultaneously injected intraperitoneally at a
dose of 100 and 10 mg/kg, respectively, for mouse per-
fusions. Isoflurane (IsoFlo, Abbott Laboratories) was ad-
ministered as a 1–3% mixture with oxygen via inhalation.
Experimental design
Mouse perfusion and tissue processing
Adult, hemizygous ChAT-IRES-Cre::Rosa-TdTomato
mice were anesthetized with ketamine/xylazine and per-
fused through the ascending aorta with 0.9% saline, fol-
lowed by 4% paraformaldehyde in 0.1 M PBS (pH 7.4).
Brains were harvested, postfixed for 2 h in 4% parafor-
maldehyde, and then stored in 30% sucrose in PBS. After
at least 72 h, brains were cut into 30-m coronal sections
on a cryostat, and floating sections were stored in 0.1 M
PBS with 0.01% sodium azide at 4°C. To visualize TdTo-
mato fluorescence, sections were directly mounted onto
slides and coverslipped with vectashield.
Primary choroid plexus epithelial cell culture and Ca2
fluorescence imaging
Primary cultures of choroid plexus epithelial cells were
prepared from dissected tissue of naïve, adult Wistar male
rats (n  6). Directly after decapitation, choroid plexus
tissue was separately isolated from the third ventricle (3V)
of the brain and then pooled across subjects to derive
sufficient cell quantity for primary culture. Thereafter, cells
were treated with collagenase Type II and TrypLE Express
(Gibco). To obtain a monolayer culture, cells were plated
on a modified recording chamber consisting of a silicon
O-ring (Sealing Devices Incorporation), mounted on a
cover glass (Warner Instruments), and treated with poly-
D-lysine coated to improve cells adhesion. Cultures
achieved confluency by 2–3 d at 10,000 cells/cm2 in
DMEM with 10% FBS exosome-depleted serum and 1
pen-strep solution (Gibco). Culture media was changed
every 2–3 d, unless otherwise specified. Cell culture
plates were maintained in a humidified 37°C incubator
containing 5% CO2. The Ca
2-sensitive dye Cal-520 (AAT
Bioquest) was reconstituted with DMSO containing 20%
pluronic F-127 (Invitrogen). Before imaging, culture me-
dium was replaced with a Ca2-containing HEPES-
buffered salt solution composed of 135 mM NaCl, 5.4 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10
mM glucose (pH 7.4). Cells were then incubated with 5
MCal-520 (AM esters) for50 min at room temperature.
Cells were washed afterward for at least 30 min, and then
nicotine was applied by pipetting a fixed aliquot (30 l) of
the diluted stock solution into the recording chamber
(470-l volume) directly above the microscope objective.
The EC50 for nicotine/ACh for the different neuronal
nAChRs subtypes range from2 to 30 M (Demuro et al.,
2001; Demuro and Parker, 2005). As our rationale was to
generate a robust response by activating all the possible
nAChRs subtypes present in the cells, we performed
experiments using 30 M nicotine. The imaging system
consisted of an inverted microscope (Olympus IX 71)
equipped with a 60 total internal reflection fluorescence
(TIRF) oil immersion objective (NA 1.45) as previously
described (Demuro and Parker, 2005). Fluorescence ex-
citation was induced with a 488-nm laser from a laser
combiner (L4C OXXIUS S.A.). Emitted fluorescence (510
nm) was detected with a green bandpass (520  20 nm)
emission filter to record Ca2 fluorescence signals gen-
erated by Cal-520. Images were captured using a sCMOS
camera (Andor Zyla 4.2) providing a final magnification of
200 nm per pixel. Image acquisition was controlled by
MicroManager open source microscopy software (https://
micro-manager.org/) connected to the computer trough a
USB2 port. The camera was set to acquire from a central
region of interest of 256  256 pixels, corresponding to
50  50 m of the specimen. Time-lapse images (frame
rate 50 fps) were captured using Micromanager software.
Images were processed using MetaMorph software pack-
age (Universal Imaging) and measurements were ex-
ported to Microcal Origin2017 (OriginLab) for analysis and
graphing. Averaged fluorescence intensities were mea-
sured from regions of interest and expressed as a pseudo
ratio (F/Fo) of the change in fluorescence (F) divided by
the resting fluorescence before treatment (Fo).
Intravenous nicotine and saline self-administration
Before catheter implantation, rats were food restricted
to 85–90% of their free-feeding body weight and trained
to press an active lever in an operant chamber (Med
Associates) for food pellets (45 mg, 5TUM, TestDiet). Rats
were trained up to a fixed-ratio 5 time out 20 s (FR5TO20)
schedule of reinforcement during 1-h sessions. Self-
administration sessions were performed using two re-
tractable levers (one active, one inactive) that extend 1cm
into the chamber. Completion of the response criteria on
the active lever resulted in delivery of the food pellet.
Responses to the inactive lever resulted in no scheduled
consequence. After achieving food-training criteria of60
pellets per session for three consecutive days, rats were
implanted with the intravenous catheters. For intravenous
surgery, rats were placed under anesthesia with an iso-
flurane (1–3%)/oxygen mixture and surgerized as de-
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scribed previously (Fowler et al., 2011). Catheters were
flushed daily via the port on the rat’s dorsal region with
heparin diluted in physiologic sterile saline solution. After
48 h of postsurgical recovery, rats were food restricted
as above and permitted to respond for food reinforcement
under the FR5TO20 schedule. Subjects were randomly
assigned into either the nicotine or saline condition (total
n  44 nicotine; n  28 saline). After reinstating food
responding across three sessions, rats in the nicotine
group were then permitted access to the 0.03 mg kg	1
training dose of nicotine for seven sessions and then
transitioned to a higher dose of nicotine (0.12 mg kg	1),
whereas the saline control were maintained on saline. To
probe for the involvement of nAChR signaling in mediating
changes in transthyretin expression, 20 min before the
last session, rats were injected with mecamylamine (2
mg/kg, s.c.) or saline (s.c.). The specific sequence of
testing was as follows: food training (5 sessions until
criterion is achieved)¡ intravenous surgery and recovery
¡ reinstated food training (two to three sessions)¡ 0.03
mg/kg/infusion nicotine (7 sessions) ¡ 0.12 mg kg	1 per
infusion nicotine (1 session; for the mecamylamine study,
vehicle/mecamylamine administered before this session).
We designed the experiment with the transition to this
moderately-high dose to have the rats actively titrate their
behavior to obtain the desired amount of nicotine. In a
prior study (Fowler et al., 2011), we found that rats will
titrate their nicotine intake to a similar level across the
dose range of 0.06–0.18 mg kg	1 per infusion, and given
the localization of the dorsal 3V (d3V) choroid plexus in
juxtaposition to the medial habenula, which is preferen-
tially activated at higher nicotine doses (Fowler et al.,
2011; Frahm et al., 2011), we hypothesized that this dose
may be particularly relevant to reveal functionally signifi-
cant processes potentially mitigating drug intake. Sub-
jects in the saline self-administration control group went
through the identical procedure as noted above, but sa-
line was provided for intravenous self-administration in
the absence of nicotine. Subjects were killed after the final
self-administration session, and saline and mecamy-
lamine-injected subjects were pseudo-yoked to the num-
ber of infusions of the nicotine subjects to normalize for
the amount of total saline intake between groups. All
subjects were within a proximate range for the amount of
saline infused via the intravenous catheter.
Choroid plexus tissue dissection
Rats were placed under isoflurane anesthesia and de-
capitated. The whole brain was removed and immediately
transferred to a Petri dish and cut along the coronal plane
at the levels of the septum and raphe nucleus with a
straight edge blade. The dorsal brain portion was trans-
ferred to a Petri dish and superglued to the bottom of the
dish, with the cerebellum and brainstem facing upward.
The dish was filled with ice cold 0.1 M PBS and placed
under a dissecting microscope. Thereafter, the cerebel-
lum was gently separated from the cerebrum tissue with
forceps, allowing the fourth ventricle to be exposed. The
choroid plexus was gently removed and verified to not
contain any attached brain tissue or dura matter via mi-
croscopic inspection. For the lateral and third choroid
plexus dissections, the middle portion of the brain was
superglued on the ventral surface to a Petri dish, and the
dish was filled with ice cold PBS and placed under the
dissecting microscope. A straight edge blade was used to
cut the corpus callosum and hippocampus along the
longitudinal fissure. Thereafter, the cortex and hippocam-
pus were gently pulled to either lateral side with forceps to
expose the d3V choroid plexus, which was removed and
visually inspected under the microscope to ensure only
the presence of the choroid plexus tissue (no attached
brain tissue). Next, to obtain the lateral ventricle choroid
plexus, the hippocampus was dislodged on each side to
reveal the lateral ventricles, and the choroid plexus was
then removed from this location. Further, the hippocam-
pus and habenula were visually inspected under the mi-
croscope to ensure that they were fully intact, and these
tissues were then biobanked. Samples were flash frozen
in a collection tube and coded with unique numbers so
that experimenters processing the tissue were blinded to
the experimental condition. Samples were assigned in a
random within group manner into analyses for RT-PCR by
a second experimenter while maintaining blinding for the
experimenter processing the tissue, and each sample was
analyzed for multiple PCR assays based on the amount of
RNA derived from each subject. Postmortem human cho-
roid plexus samples were immediately frozen on dry ice at
the time of dissection and placed in coded collection
containers. All tissue was stored at –80°C.
Human brain tissue
Postmortem human choroid plexus tissue was provided
by the University of California Irvin Brain Bank through a
collaboration. Subjects ranged in age from 49 to 59,
consisted of two men and one woman, and were classi-
fied as “control” subjects (although history of multi-drug
use was noted in one of the men and the woman; the
woman was also diagnosed with obesity). Experimenters
did not receive access to personal identifying information
regarding the human subjects. Brain tissue collection was
conducted in accordance with the University of California
Irvin Brain Bank standard operating procedure, relevant
ethical regulations, and approved human Institutional Re-
view Board protocol at University of California Irvine. In-
formed consent was provided by the legal next-of-kin with
a University of California Irvine institutional approved con-
sent form.
RNA analysis
RNA was extracted from homogenized tissue with TRI-
zol reagent (Ambion Life Technologies) via the manufac-
turer’s protocol. The quality of the RNA was determined
by a NanoDrop 2000 spectrophotometer (ThermoScien-
tific). For each sample, 100 ng of total RNA was reverse
transcribed into cDNA with the iScript cDNA synthesis kit
(Bio-Rad Laboratories). RT-qPCR was performed for
nAChR subunits, transthyretin (TTR), mir-204 and the
housekeeping genes, -actin (ACTB) or U6 (RNU6). Taq-
Man Universal Master Mix II with real-time PCR gene
expression assays for CHRNA3, CHRNA5, CHRNA7,
CHRNA4, CHRNA6, CHRNA9, CHRNA10, CHRNB4,
CHRNB2, CHRNB3, TTR, mir-204, and ACTB (control) or
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microRNA assay for miR-204 and RNU6 (control) were
used according to manufactures parameters (Applied Bio-
systems). Samples were tested in duplicate or triplicate
(depending on quantity of RNA available per dissection)
and quantified with a CFX96 RT-qPCR system (Bio-Rad).
Samples with Ct values 35 cycles were considered
outside of the range of inclusion as predetermined criteria,
and thus, these samples were determined to exhibit no
RNA expression in the tissue of interest. Normalized gene
expression (2Ct) was calculated with the equation 2^(-
actin Ct – target mRNA Ct). For nAChR subunit genes, normal-
ized values were multiplied by 10,000 to represent data as
whole numbers, and for the miRNA gene expression as-
say, normalized values were multiplied by 1000. For the
microRNA assay, normalized mi-204 expression (2Ct)
was calculated with the equation 2^(U6 Ct – target miRNA Ct).
After samples were processed, group assignment was
revealed to permit comparisons of the data.
Statistical analysis
Statistical details of experiments can be found in the
results and figure legends. Data were analyzed by t test
(two-sided, unpaired) or one-way ANOVA, followed by a
Bonferroni post hoc test with correction for multiple com-
parisons (GraphPad Prism 6), as appropriate. The crite-
rion for significance was set at p 
 0.05.
Results
Cholinergic signaling mechanisms are localized in
epithelial cells of the choroid plexus
In ChAT-IRES-Cre::ROSA26Sor-tdTomato mice, we
identified choroid plexus epithelial cells that express
ChAT, the conventional marker used to identify cholin-
ergic cells in the brain. Other brain region specific cholin-
ergic expression in these mice was representative of that
described in the literature and as previously characterized in
this mouse line (GENSAT, 2019; Chen et al., 2018), for
instance as shown in hippocampus and habenula (Fig. 1A).
Within the d3V, scattered cholinergic cells were found
throughout the choroid plexus (Fig. 1A–C). Further, choroid
plexus epithelial cells in the lateral ventricle (Fig. 1D) and
fourth ventricle (Fig. 1E) also exhibited a similar expression
profile with a subset of cholinergic-positive cells.
Nicotine directly activates a subset of epithelial
cells, inducing calcium influx
To determine whether nicotine functionally activates the
choroid plexus cells, as opposed to just being transported
through the tissue (Spector and Goldberg, 1982), we per-
formed TIRF Ca2 imaging experiments to monitor Ca2
influx into the cytosol during nicotine-mediated activation
of nAChR channels in the plasma membrane. Application
of nicotine (30 M) into the bath solution triggered a
time-dependent rise in Ca2 fluorescence signal within a
few seconds after administration (Fig. 2A,B). The emitted
fluorescence signal slowly decayed during the 30-s re-
cording window, which is in agreement with the nAChR
kinetics for receptor activation followed by desensitiza-
tion. Of note, a statistically significant robust response to
nicotine was only found in a subset (18.4%) of the cells
imaged (two-sided, unpaired t test, t(47)  7.79, p 

0.0001, R2  56; Fig. 2C). The “nonresponder” cells did
exhibit localized, low-intensity spontaneous intracellular
Ca2 signaling in each imaged field during the recording
period, verifying that all the cells were sufficiently loaded
with the calcium indicator Cal-520 (Fig. 2). Finally, cul-
tured cells were tested with 100 mM ionomycin to further
validate loading of the Cal-520 dye, and all visualized cells
responded with a high fluorescence signal (data not shown),
verifying the dye presence and cellular functionality poten-
tial. Of further note, the partial permeability to Ca2 for
nAChRs subtypes ranges from 0.8 to 4 pS. This relatively
Figure 1. Cholinergic choroid plexus epithelial cells. A, Visualization of cholinergic cells in transgenic mice expressing td-Tomato
fluorescence under the ChAT promotor. Cholinergic cells (red) are found within the dentate gyrus of the hippocampus (DG), habenula
(Hb), and the choroid plexus of the d3V (arrows). ChAT: red; DAPI nuclei: blue. Scale bar  50 m. B, Higher magnification of the
choroid plexus epithelium from the top arrow in panel A illustrates scattered expression pattern with groups of adjacent cholinergic-
positive cells. Scale bar  25 m. C, Higher magnification image of the epithelium from the bottom arrow in panel A. Scale bar  25
m. D, Cholinergic-positive cells were also identified in the lateral ventricle with a similar expression pattern. Scale bar  25 m. E,
In the fourth ventricle choroid plexus, similar ChAT expression was observed in a subset of epithelial cells. Scale bar  25 m.
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small conductance allows a large flux of Ca2 into the cells
which, by binding to the Ca2-sensitive dye, is amplified to
become a robust fluorescence signal. As such, in the TIRF
technique, it is now possible to monitor Ca2 flux trough the
opening of a single nAChRs (Demuro and Parker, 2005,
2006). Although we cannot exclude the possibility of other
components contributing to the cytosolic Ca2 rise, such as
CICR through RyRs or calcium influx through store-operated
Ca2 channels, the temporal evolution and the time to re-
sponse obtained in these experiments strongly suggest that
the fluorescence signal is due to the opening nAChRs in the
plasma membrane of these cells.
Multiple nAChR subunits exhibit region-specific
expression patterns in the choroid plexus
A variety of nAChR subunits have been documented
within the brain, and functional pentameric nAChR sub-
types include varying combinations of 2-10 and/or
2-4 subunits (Fowler et al., 2008). In the current studies,
we systematically examined the expression of nAChR
subunit mRNA in the three choroid plexus locations in
rats. Tissues were discretely dissected from each ventri-
cle location (e.g., as shown for the d3V; Fig. 3A). Interest-
ingly, differential expression profiles were discovered
based on the ventricular localization. In the lateral ventri-
cle choroid plexus (Fig. 3B), 4, 5, 2, 3, and 4 nAChR
subunits were found. In the fourth ventricle choroid plexus
(Fig. 3C), 4 and 2 nAChR subunits were expressed.
Finally, 4, 7, 2, and 3 nAChR subunits were identified
in the d3V choroid plexus (Fig. 3D). Based on the literature
for nAChR subunit stoichiometry, multiple functional re-
ceptor subtypes would be predicted across ventricular
locations, as illustrated in the figure insets (Fig. 3B–D).
The 4 and 2 nAChR subtypes are differentially
expressed across ventricular sites and nicotine self-
administration does not consistently alter subunit
expression
Given that 4 and 2 were common to all locations, we
next examined whether the level of expression signifi-
cantly varied between the sites. For the 4 nAChR sub-
unit, statistically significant differences in expression
were found between the ventricular locations (one-way
ANOVA, F(2,40)  13.69, p 
 0.0001, R
2  0.41; Fig. 4A).
Figure 2. Nicotine activates calcium signaling in choroid plexus epithelial cells in vitro. A, Time course of Ca2-dependent fluorescence signal
recorded from responding (red) and nonresponding (black) cells following application of 30 M nicotine. Traces represent average intensity from
nine responsive (red) and 40 nonresponsive (black) primary choroid plexus epithelial cells in vitro. Primary choroid plexus obtained from n 6 rats
(five cell culture plates analyzed, resulting in 49 cells quantified). B, Representative images of a responsive cell (center) and nonresponsive cells
(bottom right) captured at the time points 1–4 as indicated inA. Increasing cytosolic free Ca2 is represented by warmer colors (as depicted with
the color bar) and increasing height of each pixel. Scale bar 20 m. C, Average fluorescence signals measured at the peak of each recording
obtained during 11 separated trials; p
 0.0001. Data represent mean SEM. Central tendency (mean) and variation (SEM) values for each
are as follows: nonresponsive, –0.054 0.008 and responsive, 0.556 0.167.
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Figure 3. nAChR subunit expression in choroid plexus derived from the lateral, fourth, and d3Vs. Choroid plexus was discretely
dissected from the ventricles of the brain. A, The outer layer of cortex and hippocampus were gently separated from the midline to
allow for visualization and removal of the d3V choroid plexus with visualization via dissection microscope (left image with white arrow),
and following removal, the choroid plexus was clearly visualized as completely separate from brain tissue (right image with black
arrow). Similar dissections were conducted with microscopic visualization and verification for the lateral and fourth ventricle locations.
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Post hoc analyses revealed increased 4 nAChR subunit
mRNA expression in the fourth ventricle compared to the
lateral and 3V. For the 2 nAChR subunit, significant
differences were again found among the groups (one-way
ANOVA, F(2,34)  4.30, p  0.0217, R
2  0.20; Fig. 4B),
with post hoc analyses revealing significantly higher 2
subunit mRNA expression in the 3V choroid plexus as
compared to the lateral.
In prior studies, chronic nicotine exposure has been
found to increase radiotracer agonist binding for nAChRs
in human smokers and rodent models (Benwell et al.,
1988; Marks et al., 1992; Breese et al., 1997), suggesting
a functional upregulation of receptors. Thus, given the
differences found in the expression pattern of 4 and 2
nAChR subunits across ventricular choroid plexus sites,
we next sought to examine whether chronic nicotine in-
take would alter the mRNA expression of these subunits.
Rats were behaviorally tested in the intravenous nicotine
self-administration protocol to obtain tissue for analysis
(Fig. 5A,B), and saline self-administration subjects were
pseudo-yoked to allow for similar levels of saline intake
between groups. When comparing tissue from saline ver-
sus nicotine self-administering rats, statistically significant
differences were not found for the 4 nAChR subunit in
the choroid plexus across locations, including the lateral
ventricle (two-sided, unpaired t test, t(14) 1.11, p 0.29,
R2  0.08; Fig. 4C), fourth ventricle (two-sided, unpaired
t test, t(14)  0.47, p  0.64, R
2  0.02; Fig. 4E), and d3V
(two-sided, unpaired t test, t(14)  0.71, p  0.49, R
2 
0.03; Fig. 4G). For the 2 nAChR subunit, significant
differences between groups were also not found in the
lateral ventricle site (two-sided, unpaired t test, t(14) 
0.47, p  0.47, R2  0.04; Fig. 4D) and d3V sites (two-
sided, unpaired t test, t(14)  0.40, p  0.70, R
2  0.01;
Fig. 4H). However, the fourth ventricle choroid plexus
comparison did reveal a decrease in 2 nAChR mRNA
with nicotine self-administration (two-sided, unpaired t
test, t(14)  2.52, p  0.0245, R
2  0.31; Fig. 4F).
Nicotine self-administration selectively increases the
mRNA expression of the choroid plexus-specific
protein, transthyretin, in the d3V
To investigate whether nicotine differentially acts on the
choroid plexus in a site-specific manner, we examined
expression of the choroid plexus-specific protein, tran-
sthyretin, in rats self-administering saline or nicotine (for
nicotine self-administration data, see Fig. 5). A prior study
found that nicotine exposure increases transthyretin
mRNA in gross dissections of the hippocampus and sur-
rounding ventricles, as well as the protein in the CSF (Li
et al., 2000), but these investigations did not specifically
isolate the choroid plexus tissue or examine expression
across the choroid plexus ventricular sites. Further, since
transthyretin protein is released from the choroid plexus
and into the CSF in a dynamic manner, we focused on
expression of the mRNA transcript 30-min following the
end of the self-administration session with discrete dis-
sections from each of the ventricular locations. Interest-
ingly, a statistically significant increase was found in
transthyretin mRNA expression with nicotine self-ad-
ministration in the d3V, which is localized in proximity to
the medial habenula. Further, this increased expression
was prevented with pretreatment of mecamylamine (2
mg/kg; one-way ANOVA, F(2,13) 11.31, p 0.0014, R
2
0.6351; Fig. 6C). No differences in expression were found
in the lateral ventricle (two-sided, unpaired t test, t(14) 
0.14, p  0.8879, R2  0.001; Fig. 6A) or fourth ventricle
(two-sided, unpaired t test, t(18)  0.15, p  0.8804, R
2 
0.001; Fig. 6B) choroid plexus tissues, identifying region-
specific effects of nicotine’s actions on this mechanism.
Differential expression of mir-204 in the d3V choroid
plexus with nicotine
Given that miRNAs may be involved in the choroid
plexus as an alternate mechanism of mediating cellular
function, we next examined whether intravenous nicotine
self-administration alters miRNA expression in the cho-
roid plexus (for nicotine self-administration data, see Fig.
5). Specifically, mir-204 is localized to the sixth intron of
the transient receptor potential melastatin 3 (TRPM3
gene) and is expressed under the control of this gene
promotor in high density in the choroid plexus (Oberwin-
kler et al., 2005; Li et al., 2016). In a preliminary mir-204
gene expression assay (n  3/group), we found that
nicotine self-administration induced a significant increase
in mir-204 expression in the d3V choroid plexus (two-
sided, unpaired t test, t(4)  3.98, p  0.0164, R
2  0.798;
mean  SEM: Saline: 10.82  5.19 and Nicotine: 37.53 
4.25; p 
 0.05) as compared to saline. However, group
differences were not found in the lateral ventricle (two-
sided, unpaired t test, t(4)  0.797, p  0.4699, R
2 
0.137; mean  SEM: Saline: 36.68  11.80 and Nicotine:
52.97  16.66) or fourth ventricle (two-sided, unpaired t
test, t(4)  0.185, p  0.8624, R
2  0.009; mean  SEM:
continued
B–D, The expression of nAChR subunits was examined in choroid plexus tissue from rats (n 8–15/group, specific number per group
denoted on each bar). B, In the lateral ventricle (LV), mRNA expression was found for the 4 (Chrna4), 5 (Chrna5), 2 (Chrnb2), 3
(Chrnb3), and 4 (Chrnb4) nAChR subunits. Putative nAChR subtype schematics are graphically illustrated (insert). Statistical data are
as follows [central tendency (mean)  variation (SEM), lower 95% confidence interval, upper 95% confidence interval]: 4: 3.35 
0.34, 2.61, 4.09; 5: 1.44  0.29, 0.77, 2.10; 2: 2.37  0.28, 1.77, 2.97; 3: 0.32  0.32, 0, 1.03; and 4: 1.50  0.42, 0.56, 2.45.
C, In the fourth ventricle (4V), only 4 (Chrna4) and 2 (Chrnb2) mRNAs were detected, and thus, the 42 nAChR subtype may be
present (schematic insert). Statistical data are (mean  SEM, lower CI, upper CI): 4: 8.93  1.18, 6.38, 11.47 and 2: 2.77  0.38,
1.93, 3.61. D, In the d3V, subunit expression consisted of 4 (Chrna4), 7 (Chrna7), 2 (Chrnb2), and 3 (Chrnb3), which allows for
four different putative nAChR subtypes (schematic insert). Statistical data are (mean  SEM, lower CI, upper CI): 4: 5.86  0.53,
4.71, 7.01; 7: 2.12  0.67, 0.61, 3.62; 2: 5.16  1.19, 2.53, 7.79; and : 21.12  8.25, 2.09, 40.14. For each nAChR gene above,
expression data were normalized to expression of -actin as the endogenous control. nd not detected based on the predetermined
RT-qPCR criteria (Ct value  35). Data represent mean normalized values  SEM.
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Figure 4. Differential expression of 4 and 2 nAChR subunits across choroid plexus sites. A, B, Given that 4 and 2 subunits were
found in all choroid plexus sites, their relative expression was compared under baseline conditions (n 12–15/group, specific number
per group denoted on each bar). A, For the 4 nAChR subunit, significantly increased expression was found in choroid plexus from
the fourth ventricle compared to tissue from the lateral and d3V. Post hoc corrected for multiple comparisons; p 
 0.05, p 

0.001. Central tendency (mean) and variation (SEM) values for each are as follows: LV: 3.350 0.34; 4V: 8.925 1.18; and d3V: 5.861
 0.53. For each nAChR gene, expression data were normalized to expression of -actin. B, With regard to the 2 nAChR subunit,
significantly increased expression was found in the d3V choroid plexus as compared to the lateral ventricle (LV). Post hoc corrected
for multiple comparisons; p 
 0.05. Central tendency (mean) and variation (SEM) values for each are as follows: LV: 2.371  0.27;
4V: 2.773  0.38; and d3V: 5.156  1.19). 4V: fourth ventricle. For each nAChR gene, expression data were normalized to expression
of -actin. Data represent mean normalized values  SEM. C–H, Expression of 4 and 2 nAChR subunits with nicotine or saline
self-administration (n  8/group as denoted on each bar). Following saline or nicotine self-administration in rats, normalized
expression levels of 4 and 2 nAChR subunits were compared. For the 4 nAChR subunit (left panels), similar mRNA expression
levels were found with saline and nicotine self-administration in choroid plexus from the (C) LV, (E) 4V, and (G) d3V. For the 2 nAChR
subunit (right panels), differences were not found in mRNA expression in the (D) LV or (H) d3V, whereas a significant decrease with
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Saline: 53.16  7.31 and Nicotine: 56.62  17.23). While
the gene expression assay normalizes to the common
housekeeping gene, -actin, it may also identify other
sections of the TRPM3 gene, in addition to mir-204.
Therefore, we next used the more selective mir-204
microRNA assay that normalizes to U6, the preferred
normalization factor for miRNA analysis in the field, to
specifically validate the differences found with the gene
assay. In the d3V choroid plexus, a significant increase
in mir-204 expression was again evidenced with nico-
tine self-administration (two-sided, unpaired t test, t(11)
 2.70, p  0.0103, R2  0.399; Fig. 7C), thus confirm-
ing the prior findings. Differences in mir-204 expression
were not found between groups in the choroid plexus of
the lateral ventricle (two-sided, unpaired t test, t(16) 
0.60, p  0.555, R2  0.022) or fourth ventricle (two-
sided, unpaired t test, t(8)  2.02, p  0.078, R
2 
0.339).
Human choroid plexus expresses nAChRs,
transthyretin and mir-204
Since nAChR subtype distribution can vary across spe-
cies (Gotti et al., 1997), we next validated the expression
of nAChR subunit mRNA in tissue from humans. Expres-
sion of 4, 7, 2 and 3 nAChR subunits were identified,
with 4, 7 and 3 localized to the lateral ventricle (Fig.
8A) and 4, 7, and 2 localized to the 3V (Fig. 8B).
Expression of transthyretin (Fig. 8C) and mir-204 (Fig. 8D)
were also found in both the lateral and 3V human choroid
plexus tissues.
Discussion
Together, the current studies reveal that activation of
nicotinic receptors during nicotine self-administration in-
duces an upregulation in transthyretin specifically within
the d3V choroid plexus. This effect was reversed by the
nicotinic receptor antagonist, mecamylamine, demon-
continued
nicotine was found in the (F) 4V choroid plexus; p 
 0.05. Central tendency (mean) and variation (SEM) values (C–H) are as follows:
4 LV - Saline: 3.758  0.46; Nicotine: 4.600  0.60; 4 4V - Saline: 10.60  1.60; Nicotine: 11.74  1.79; 4 d3V - Saline: 5.915
 0.87; Nicotine: 7.015  1.28; 2 LV - Saline: 2.978  0.19; Nicotine: 3.310  0.41; 2 4V - Saline: 2.953  0.37; Nicotine: 1.762
 0.30; 2 d3V - Saline: 5.319  0.66; and Nicotine: 4.732  1.31. For each nAChR gene, expression data were normalized to
expression of -actin. Data represent mean normalized values  SEM.
Figure 5. Intravenous nicotine self-administration in rats. Rats were trained in the intravenous nicotine self-administration protocol;
access to the acquisition dose of 0.03 mg kg	1 per infusion was provided for 7 d, followed by 0.12 mg kg	1 per infusion on the eighth
session. A, The number of nicotine infusions across sessions during nicotine self-administration corresponds to tissue analyzed for
studies shown in Figures 4, 6, 7 (n  33). B, On the final session, the subjects shown in Figure 5A self-administered a mean of 1.1
mg/kg nicotine (0.09 SEM). C, For the data presented in Figure 6C, groups were tested across doses as described above but were
administered either vehicle or mecamylamine before the self-administration session on session 8 (n  5–6/group). D, For session 8,
a significant decrease in the amount of nicotine consumed was found in the mecamylamine group compared to the vehicle group;
p 
 0.05. The mean nicotine intake (mg/kg)  SEM for each group was: Vehicle: 1.248  0.16 and Mecamylamine: 0.62  0.122.
Specific subject numbers per group are denoted on the bar graphs. Data represent mean values  SEM.
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strating a direct effect of nicotine on the nAChRs in me-
diating gene expression. In addition to changes in
transthyretin expression, nicotine also site specifically in-
creased the expression of mir-204, a miRNA transcript
found in high abundance within the choroid plexus. These
effects on the choroid plexus could be attributed to en-
dogenous cholinergic signaling mechanisms within the
choroid plexus. Specifically, a subset of epithelial cells
was found to express the cholinergic marker ChAT, and
nAChR subunits were identified in all of the choroid plexus
ventricular sites. Of further note, the specific nAChR sub-
unit expression varied across ventricular regions, provid-
Figure 6. Transthyretin expression in the choroid plexus with saline or nicotine self-administration. Expression of choroid plexus
specific transthyretin mRNA was examined in rats self-administering saline or nicotine (n  5–12/group, specific number per group
denoted on each bar). A, In the lateral ventricle (LV), differences were not found between groups in transthyretin expression. B, In the
fourth ventricle (4V), no differences were found in transthyretin expression. C, In the dorsal third ventricle (d3V), significant
upregulation of transthyretin was found with nicotine self-administration, an effect that was reversed with pretreatment of mecam-
ylamine (MEC) before nicotine self-administration; p 
 0.001. The photomicrograph on the right displays the localization of the
choroid plexus (CP) in the d3V, which is in proximity to the habenula (Hb). Central tendency (mean) and variation (SEM) values for each
are as follows: LV - Saline: 145.9  32.23; Nicotine: 152.9  36.57; 4V - Saline: 372.8  57.27; Nicotine: 357.3  73.58; d3V - Saline:
214.5  25.81; Nicotine: 455.0  61.43; and Mecamylamine/Nicotine: 214.3  29.21. For all of the above, expression data were
normalized to expression of -actin. Data represent mean normalized values  SEM.
Figure 7. Nicotine mediated changes in expression of mir-204 in the choroid plexus. The expression of mir-204 was examined following
saline or nicotine self-administration for each of the choroid plexus sites (n 5–9/group, specific number per group denoted on each bar).
A, Differences in expression of mir-204 were not found in the lateral ventricle choroid plexus between the nicotine and saline self-
administration groups. Central tendency (mean) and variation (SEM) values for each are as follows: Saline: 6.43  1.38 and Nicotine: 8.98
 4.01. B, In the fourth ventricle choroid plexus, statistically significant group differences were not found. Central tendency and variation:
Saline: 14.32  0.87 and Nicotine: 9.46  2.24. C, In the d3V choroid plexus, nicotine self-administration induced a significant increase in
the expression of mir-204 as compared to saline control. Central tendency (mean) and variation (SEM) values for each are as follows: Saline:
9.004  1.32 and Nicotine: 14.49  1.36; p 
 0.05. Data represent mean normalized values  SEM.
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ing further evidence of the ability of nicotine to exert
site-specific effects on choroid plexus mechanisms. The
nAChRs were also shown to be functionally active as
nicotine directly led to increased cellular excitability, as
evidenced with Ca2 influx. Finally, cholinergic signaling
mechanisms were also discovered in human choroid
plexus, supporting the translational relevance of the cur-
rent studies. Taken together, these findings expand our
understanding of the extent of cholinergic function in the
brain and elucidate a previously unrecognized source of
signaling that may be alternately regulated under states of
cholinergic dysfunction and/or with pharmacological ac-
tivation of nAChRs, such as during nicotine dependence.
Site-specific differences in the choroid plexus
While prior characterization of the choroid plexus has
assumed similar function across ventricular sites, recent
findings in embryonic mice have suggested differential
transcript expression during development (Lun et al.,
2015b). The current findings provide novel evidence of
region-specific function of the choroid plexus during
adulthood, as nicotine self-administration induced differ-
ences in gene and miRNA expression selectively in the
d3V. The reason for such different actions of nicotine may
be attributed to the nAChR subtype expressed within the
discrete tissue locations. In the d3V, the 4, 7, 2, and
3 nAChR subtypes were found in the choroid plexus,
consistent with expression patterns exhibited in this re-
gion in nAChR subunit transgenic mice (GENSAT, 2019).
The 4 and 2 subunits can combine together to form a
functional receptor subtype, and the 3 subunit has been
shown to co-assemble with the 42 subtype as well. In
contrast, the 7 subunit most often forms a homomeric
structure, although some reports suggest the presence of
an 72 functional subtype (Wu et al., 2016). Moreover,
the 42 and 7 nAChR subtypes demonstrate functional
Figure 8. Expression of nAChR subunits, transthyretin and mir-204 in human choroid plexus tissue. Choroid plexus from the lateral
and third ventricle (3V) were examined from postmortem humans (n  3 for all analyses shown). A, In the lateral ventricle (LV), mRNA
expressions of 4 (CHRNA4), 7 (CHRNA7), and 3 (CHRNB3) were detected. Statistical data are as follows Central tendency (mean)
 variation (SEM), lower 95% confidence interval, upper 95% confidence interval: 4: 63.51  13.39, 5.88, 121.1; 7: 38.97  8.83,
0.95, 76.98; and 3: 23.97 14.55, 0, 86.56. B, In the 3V, mRNA expressions of 4 (CHRNA4), 7 (CHRNA7), and 2 (CHRNB2) were
identified. Statistical data are: 4: 37.30  7.90, 3.33, 71.28; 7: 38.06  28.76, 0, 161.8; and 2: 5.62  1.92, 0, 13.86. C,
Transthyretin expression was found at similar levels in the lateral and 3V of human tissue. Statistical data (mean  SEM, lower CI,
upper CI) are: LV: 216.7  50.10, 1.15, 432.3 and 3V: 192.6  117.2, 0, 696.8. D, Expression of mir-204 was abundantly localized
in the 3V choroid plexus, with lower levels found in the lateral ventricle tissue. Statistical data (mean  SEM, lower CI, upper CI) are:
LV: 25.91 16.36, 0, 96.31 and 3V: 151.5 139.1, 0, 749.9. Expression data were normalized to expression of -actin (n 3 for each
gene/region). For all of the above, the absence of a bar above the denoted nAChR subunit indicates that the mRNA was not detected
(nd) based on the predetermined RT-qPCR criteria (Ct value  35). Data represent mean normalized values  SEM.
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differences with ligand binding. The 42-containing
nAChR subtype has a high probability of opening and
slower desensitization rate (Li and Steinbach, 2010),
whereas the 7 nAChR subtype exhibits higher calcium
permeability, lower probability of opening, and rapid de-
sensitization (Williams et al., 2011). Notably, the 42 and
7 receptor subtypes have been implicated in learning
and memory, drug reinforcement, anxiety, schizophrenia,
and immune function (Fowler et al., 2008; Dani, 2015; Wu
et al., 2016). The latter function provides an important
consideration given that the choroid plexus modulates
innate immunity and viral infiltration into the brain (Skok
et al., 2005; Vercellino et al., 2008; Ridder et al., 2014;
Zhang et al., 2015; Wu et al., 2016). In our Ca2 imaging
study, we provide further evidence that functional
nAChRs are present in choroid plexus epithelial cells, as
nicotine exposure resulted in substantial intracellular
Ca2 influx. These studies also documented a subpopu-
lation of cells exhibiting excitability with nicotine applica-
tion, which parallels the relative proportion of cholinergic
epithelial cells found in the choroid plexus in the fluores-
cence reporter mice. Moreover, the temporal evolution of
the Ca2 responses in vitro closely mimics the temporal
patterns of Ca2 fluxes found with 42 nAChRs in dif-
ferent preparations (Vernino et al., 1994; Demuro et al.,
2001).
Of further note, we did not detect any significant differ-
ences in nAChR subunit mRNA expression with intrave-
nous nicotine self-administration, with the exception of a
decrease in 2 subunit expression in the fourth ventricle.
In prior studies (Marks et al., 1992; Pauly et al., 1996),
nAChR binding has been shown to increase at the cellular
membrane during chronic nicotine administration via im-
planted minipump, whereas limited differences in mRNA
expression were evidenced. Since nicotine has been
shown to act as a ‘molecular chaperone’ to facilitate the
trafficking and insertion of 4-containing and 2-
containing nAChR subtypes into the cell membrane
(Kuryatov et al., 2005; Srinivasan et al., 2011; Henderson
et al., 2014), it is possible that altered expression of
nAChRs on the cell membrane could have been induced
under the self-administration conditions, an intriguing
possibility that will need to be examined in further studies.
Potential relevance to human disease
The specific effect of nicotine on transthyretin expres-
sion within the d3V has several implications. After being
released from the choroid plexus into the CSF, transthy-
retin transports thyroxine and retinol/retinol binding pro-
tein throughout the brain. Interestingly, differences in
transthyretin levels have been noted in clinical popula-
tions. For instance, patients with schizophrenia have been
found to have reduced levels of transthyretin and altered
nicotinic receptor signaling has been associated with
schizophrenia in humans and animal models (Diwan et al.,
1998; Wan et al., 2006; Koukouli et al., 2017), suggesting
a potential relevance of choroid plexus function in the
disease state. With regard to Alzheimer’s disease and
dementia, a decrease in transthyretin is correlated with
increased risk of severe dementia (Serot et al., 1997).
Transthyretin has been proposed to prevent A fibrillo-
genesis to limit disease progression (Schwarzman et al.,
1994; Golabek et al., 1995). Increased nicotine consump-
tion in smokers has also been correlated with decreased
risk of Alzheimer’s disease (van Duijn and Hofman, 1991),
and in mice, nicotine treatment reduces the presence of
insoluble A (Nordberg et al., 2002; Inestrosa et al., 2013).
Although prior findings appeared to support the hypoth-
esis that nicotine may act through transthyretin to bene-
ficially modify Alzheimer’s disease pathology (Li et al.,
2000), findings from the current study suggest that any
beneficial effects of transthyretin would be limited to re-
gions in close proximity to the d3V. Further, it is worth-
while to note that in our analysis of the human tissue,
variability was noted in the levels of transcript expression,
which could potentially be attributed to individual differ-
ences among the subjects (e.g., sex; ethnic background;
history of drug use: tobacco, psychostimulants, or alco-
hol). Moreover, reduced levels of mir-204 have been
found in the CSF of patients with frontotemporal dementia
(FTD), and as such, this miRNA has been proposed to be
a biomarker for the disease state (Nissen et al., 2018). In
light of the current findings, such a proposed biomarker
approach will need to consider smoking status since
nicotine may mitigate the level of mir-204 expression.
Further, it will be important in future studies to more
directly determine whether mir-204 alters gene expres-
sion underlying pathology affecting memory function and
whether nicotine could modulate any changes in this
regard.
Conclusions
The current studies identify a previously unrecognized
source of cholinergic signaling within the brain and iden-
tify the direct mechanism through which nicotine acts on
this tissue to alter function. Findings derived from the
human choroid plexus further support the translational
relevance of the rodent studies. In addition to important
implications for tobacco/nicotine dependence, the cur-
rent findings elucidate a mechanism through which cho-
linergic signaling may impact global brain function via
release of factors into the CSF, which could further our
understanding of multiple disease states characterized by
cholinergic dysfunction, and these findings may also have
important implications for patients prescribed pharmaco-
therapeutics with actions on the cholinergic system.
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